Evidence map›Paper›PMID 30126069›Full record

ArticleThoracic cancer2018

Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series.

Daiki Ogawara, Hiroshi Soda, Hiromi Tomono, Keisuke Iwasaki, Takuya Hara, Saeko Jinnai, Takatomo Funayama, Daisuke Okuno, Hirokazu Taniguchi, Masataka Yoshida and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Daiki OgawaraDepartment of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
Hiroshi SodaDepartment of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.ORCID 0000-0003-4993-1837
Hiromi TomonoDepartment of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
Keisuke IwasakiDepartment of Pathology, Sasebo City General Hospital, Nagasaki, Japan.
Takuya HaraDepartment of Pathology, Sasebo City General Hospital, Nagasaki, Japan.
Saeko JinnaiDepartment of Pathology, Sasebo City General Hospital, Nagasaki, Japan.
Takatomo FunayamaPathology Laboratory, Morphotechnology Company Limited, Sapporo, Japan.
Daisuke OkunoDepartment of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
Hirokazu TaniguchiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Masataka YoshidaDepartment of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
Tatsuhiko HaradaDepartment of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
Asuka UmemuraDepartment of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
Yuichi FukudaDepartment of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
Hiroyuki YamaguchiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe combination of PD-1 inhibitors and cytotoxic drugs is reported to enhance anti-tumor activity in non-small cell lung cancer; however, the underlying synergistic mechanisms remain uncertain. This retrospective case series was designed to investigate objective response and survival rates of salvage chemotherapy following nivolumab and explore the immunohistochemical profiles of tumor-infiltrating immune cells.

methodsThe medical records of 37 patients administered nivolumab were retrospectively reviewed. Overall response rate and progression-free survival were compared among three groups: salvage chemotherapy following nivolumab, nivolumab therapy alone, and chemotherapy preceding nivolumab.

resultsEight cases met the study criteria. Salvage chemotherapy following nivolumab improved the overall response rate to 62.5% (95% confidence interval [CI] 34.4-90.6%; P = 0.004) and median progression-free survival to six months (95% CI 4.6-7.4; P = 0.016), compared to nivolumab alone and preceding chemotherapy. The response to salvage chemotherapy was not associated with tumor PD-L1 expression. A partial response was achieved in four cases with ≤ 5% and ≤ 2.9 cells/mm

conclusionSalvage chemotherapy following nivolumab improved anti-tumor activity regardless of tumor PD-L1 status, but nivolumab following chemotherapy did not. The presence of few PD-1

Indexed as

AgedCarcinoma, Non-Small-Cell LungFemaleHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedNivolumabRetrospective StudiesSalvage TherapyTumor MicroenvironmentNivolumabExhausted T cellimmunotherapyPD-1salvage chemotherapy

Identifiers

PMID30126069
PMCPMC6166078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.